Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
about
Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.Inactivated influenza vaccines: recent progress and implications for the elderly.Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccinesRecent progress in adjuvant discovery for peptide-based subunit vaccinesAn overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesImmunosenescence and Challenges of Vaccination against Influenza in the Aging Population.The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigen-specific cellular and humoral immunity.Formulation and delivery of vaccines: Ongoing challenges for animal management.Clinical applications of virosomes in cancer immunotherapy.Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs.Epaxal: a virosomal vaccine to prevent hepatitis A infection.Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen.Influenza virosomes as a vaccine adjuvant and carrier system.Immunization of patients with autoimmune inflammatory rheumatic diseases (the EULAR recommendations).Influenza virosomes as vaccine adjuvant and carrier system.Preservation of influenza virosome structure and function during freeze-drying and storage.Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Vaccine adjuvants: smart components to boost the immune system.
P2860
Q30353863-1B9F2F21-6967-4F1E-9797-6B4F92063A2DQ30373149-C979D439-F2BC-4388-AF78-0FD1B06F2AA5Q30399057-7137D684-F2D3-4ED3-BE5A-27716197DC8BQ30408295-86FB5FCF-F233-4D66-86B8-D6BCBFCDBD33Q34033780-4570AFB1-10E8-498D-B2F7-872303D7E4A6Q35100779-D7F7B845-56BC-4BDB-A1C9-DB2D5648D022Q35874111-3269474D-F632-4922-BB46-6EF4D161684AQ36191605-DD2AC034-6541-413F-9D68-6BCA55C96733Q36470265-690F5972-F7A2-4C6B-BB13-980F2344A206Q36627236-C379557B-E7D6-4C42-8045-C681ED7E544AQ36968260-D14AE897-9323-45B2-9510-2DC13C5A1E5FQ37087655-E7CDBACC-FA0D-40FE-9272-85F415062D29Q37290088-8D9A656A-4DD7-4747-9124-A649FAD97A15Q37740679-E6EBDB18-C88C-4B8B-A7D1-4C473EFD99E9Q37867100-AE10D4DA-7BD0-457B-9D0A-3249CBA481E0Q37974891-E6F7B94B-1AAA-4495-BE7F-221374956991Q38124062-0CD33CE3-29F7-4828-BBC3-37DF6EC49D16Q38296249-2CB843E2-B62A-4A5C-A132-4238BD1A6F86Q38886698-0C31A2E5-0462-4E0E-96F3-4D16187ADC89Q38971243-772DC417-6D7B-4012-A564-38ECBDE194D0Q40355127-17F32489-DA6F-4DA9-B346-FCA2F1116082Q40752357-1A0B58EF-9B88-47C0-9314-EE04E2A49336Q50063256-5205A1AD-8019-4C38-857A-DD649D9D2A20
P2860
Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Virosome-mediated delivery of ...... totoxic T lymphocyte activity.
@en
type
label
Virosome-mediated delivery of ...... totoxic T lymphocyte activity.
@en
prefLabel
Virosome-mediated delivery of ...... totoxic T lymphocyte activity.
@en
P50
P1433
P1476
Virosome-mediated delivery of ...... totoxic T lymphocyte activity.
@en
P2093
Arjan de Mare
Laura Bungener
P304
P356
10.1016/J.VACCINE.2004.09.002
P407
P577
2005-01-01T00:00:00Z